|
1
|
Wu C, Kraft P, Zhai K, Chang J, Wang Z, Li
Y, Hu Z, He Z, Jia W, Abnet CC, et al: Genome-wide association
analyses of esophageal squamous cell carcinoma in Chinese identify
multiple susceptibility loci and gene-environment interactions. Nat
Genet. 44:1090–1097. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brown LM, Devesa SS and Chow WH: Incidence
of adenocarcinoma of the esophagus among white Americans by sex,
stage, and age. J Natl Cancer Inst. 100:1184–1187. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamangar F, Malekzadeh R, Dawsey SM and
Saidi F: Esophageal cancer in Northeastern Iran: A review. Arch
Iran Med. 10:70–82. 2007.PubMed/NCBI
|
|
4
|
Rubenstein JH and Shaheen NJ:
Epidemiology, diagnosis, and management of esophageal
adenocarcinoma. Gastroenterology. 149:302–317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lai J, Yang F, Zhang W, Wang Y, Xu J, Song
W, Huang G, Gu J and Guan X: TAp73 and ΔNp73 have opposing roles in
5-aza-2′-deoxycytidine-induced apoptosis in breast cancer cells.
Mol Cells. 37:605–612. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
El Baroudi M, La Sala D, Cinti C and
Capobianco E: Pathway landscapes and epigenetic regulation in
breast cancer and melanoma cell lines. Theor Biol Med Model.
11(Suppl 1): S82014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Momparler RL: Epigenetic therapy of cancer
with 5-aza-2′-deoxycytidine (decitabine). Semin Oncol. 32:443–451.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lemaire M, Momparler LF, Bernstein ML,
Marquez VE and Momparler RL: Enhancement of antineoplastic action
of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia.
Anticancer Drugs. 16:301–308. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Momparler RL and Bovenzi V: DNA
methylation and cancer. J Cell Physiol. 183:145–154. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahn JS, Kim YK, Min YH, Cheong JW, Jang
JH, Jung CW, Kim IH, Yoon HJ, Lee HG, Sohn SK, et al: Azacitidine
pre-treatment followed by reduced-intensity stem cell
transplantation in patients with higher-risk myelodysplastic
syndrome. Acta Haematol. 134:40–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maurillo L, Venditti A, Spagnoli A,
Gaidano G, Ferrero D, Oliva E, Lunghi M, D'Arco AM, Levis A,
Pastore D, et al: Azacitidine for the treatment of patients with
acute myeloid leukemia: Report of 82 patients enrolled in an
Italian Compassionate Program. Cancer. 118:1014–1022. 2012.
View Article : Google Scholar
|
|
12
|
Sudan N, Rossetti JM, Shadduck RK, Latsko
J, Lech JA, Kaplan RB, Kennedy M, Gryn JF, Faroun Y and Lister J:
Treatment of acute myelogenous leukemia with outpatient
azacitidine. Cancer. 107:1839–1843. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Egger G, Liang G, Aparicio A and Jones PA:
Epigenetics in human disease and prospects for epigenetic therapy.
Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cho YH, Yazici H, Wu HC, Terry MB,
Gonzalez K, Qu M, Dalay N and Santella RM: Aberrant promoter
hypermethylation and genomic hypomethylation in tumor, adjacent
normal tissues and blood from breast cancer patients. Anticancer
Res. 30:2489–2496. 2010.PubMed/NCBI
|
|
15
|
Esteller M, Sanchez-Cespedes M, Rosell R,
Sidransky D, Baylin SB and Herman JG: Detection of aberrant
promoter hypermethylation of tumor suppressor genes in serum DNA
from non-small cell lung cancer patients. Cancer Res. 59:67–70.
1999.PubMed/NCBI
|
|
16
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Palmisano WA, Divine KK, Saccomanno G,
Gilliland FD, Baylin SB, Herman JG and Belinsky SA: Predicting lung
cancer by detecting aberrant promoter methylation in sputum. Cancer
Res. 60:5954–5958. 2000.PubMed/NCBI
|
|
18
|
Mikhailenko DS and Kushlinskii NE: The
somatic mutations and aberrant methylation as potential genetic
markers ofurinary bladder cancer. Klin Lab Diagn. 61:78–83. 2016.In
Russian. PubMed/NCBI
|
|
19
|
Vaissière T1, Hung RJ, Zaridze D, Moukeria
A, Cuenin C, Fasolo V, Ferro G, Paliwal A, Hainaut P, Brennan P, et
al: Quantitative analysis of DNA methylation profiles in lung
cancer identifies aberrant DNA methylation of specific genes and
its association with gender and cancer risk factors. Cancer Res.
69:243–252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kaz AM and Grady WM: Epigenetic biomarkers
in esophageal cancer. Cancer Lett. 342:193–199. 2014. View Article : Google Scholar
|
|
21
|
Bussemakers MJ, van Bokhoven A, Mees SG,
Kemler R and Schalken JA: Molecular cloning and characterization of
the human E-cadherin cDNA. Mol Biol Rep. 17:123–128. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu Q, Guo Q, Chen L and Liu S:
Clinicopathological significance and potential drug targeting of
CDH1 in lung cancer: A meta-analysis and literature review. Drug
Des Devel Ther. 9:2171–2178. 2015.PubMed/NCBI
|
|
23
|
Karayiannakis AJ, Syrigos KN, Chatzigianni
E, Papanikolaou S, Alexiou D, Kalahanis N, Rosenberg T and
Bastounis E: Aberrant E-cadherin expression associated with loss of
differentiation and advanced stage in human pancreatic cancer.
Anticancer Res. 18:4177–4180. 1998.
|
|
24
|
Zheng Z, Pan J, Chu B, Wong YC, Cheung AL
and Tsao SW: Downregulation and abnormal expression of E-cadherin
and beta-catenin in nasopharyngeal carcinoma: Close association
with advanced disease stage and lymph node metastasis. Hum Pathol.
30:458–466. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oka H, Shiozaki H, Kobayashi K, Inoue M,
Tahara H, Kobayashi T, Takatsuka Y, Matsuyoshi N, Hirano S,
Takeichi M, et al: Expression of E-cadherin cell adhesion molecules
in human breast cancer tissues and its relationship to metastasis.
Cancer Res. 53:1696–1701. 1993.PubMed/NCBI
|
|
26
|
Cui H, Wang L, Gong P, Zhao C, Zhang S,
Zhang K, Zhou R, Zhao Z and Fan H: Deregulation between miR-29b/c
and DNMT3A is associated with epigenetic silencing of the CDH1
gene, affecting cell migration and invasion in gastric cancer. PLoS
One. 10:e01239262015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Sun J, Wang B, Ren JC, Su W and
Zhang T: MicroRNA-10b triggers the epithelial-mesenchymal
transition (EMT) of laryngeal carcinoma Hep-2 cells by directly
targeting the E-cadherin. Appl Biochem Biotechnol. 176:33–44. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Viotti M, Nowotschin S and Hadjantonakis
AK: SOX17 links gut endoderm morphogenesis and germ layer
segregation. Nat Cell Biol. 16:1146–1156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang W, Glöckner SC, Guo M, Machida EO,
Wang DH, Easwaran H, Van Neste L, Herman JG, Schuebel KE, Watkins
DN, et al: Epigenetic inactivation of the canonical Wnt antagonist
SRY-box containing gene 17 in colorectal cancer. Cancer Res.
68:2764–2772. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jia Y, Yang Y, Liu S, Herman JG, Lu F and
Guo M: SOX17 antagonizes WNT/β-catenin signaling pathway in
hepatocellular carcinoma. Epigenetics. 5:743–749. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin D, Jia Y, Yu Y, Brock MV, Herman JG,
Han C, Su X, Liu Y and Guo M: SOX17 methylation inhibits its
antagonism of Wnt signaling pathway in lung cancer. Discov Med.
14:33–40. 2012.PubMed/NCBI
|
|
32
|
Fu D, Ren C, Tan H, Wei J, Zhu Y, He C,
Shao W and Zhang J: Sox17 promoter methylation in plasma DNA is
associated with poor survival and can be used as a prognostic
factor in breast cancer. Medicine (Baltimore). 94:e6372015.
View Article : Google Scholar
|
|
33
|
Kuo IY, Chang JM, Jiang SS, Chen CH, Chang
IS, Sheu BS, Lu PJ, Chang WL, Lai WW and Wang YC: Prognostic CpG
methylation biomarkers identified by methylation array in
esophageal squamous cell carcinoma patients. Int J Med Sci.
11:779–787. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu X, Chen Z, Zhao X, Wang J, Ding D, Wang
Z, Tan F, Tan X, Zhou F, Sun J, et al: MicroRNA-25 promotes cell
migration and invasion in esophageal squamous cell carcinoma.
Biochem Biophys Res Commun. 421:640–645. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee EJ, Lee BB, Han J, Cho EY, Shim YM,
Park J and Kim DH: CpG island hypermethylation of E-cadherin (CDH1)
and integrin alpha4 is associated with recurrence of early stage
esophageal squamous cell carcinoma. Int J Cancer. 123:2073–2079.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y,
Ueda J, Wei W, Inoue M and Tanaka H: Epidemiology of esophageal
cancer in Japan and China. J Epidemiol. 23:233–242. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leonard GD and Reilly EM: Post-operative
chemotherapy improves disease-free survival, but not overall
survival in people with oesophageal squamous cell carcinoma. Cancer
Treat Rev. 30:473–477. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen HX and Wang Z: Retrospective study of
adjuvant chemotherapy effects on survival rate after three-field
lymph node dissection for stage IIA esophageal cancer. Asian Pac J
Cancer Prev. 16:5169–5173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yun H, Damm F, Yap D, Schwarzer A,
Chaturvedi A, Jyotsana N, Lübbert M, Bullinger L, Döhner K, Geffers
R, et al: Impact of MLL5 expression on decitabine efficacy and DNA
methylation in acute myeloid leukemia. Haematologica. 99:1456–1464.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Öz S, Raddatz G, Rius M, Blagitko-Dorfs N,
Lübbert M, Maercker C and Lyko F: Quantitative determination of
decitabine incorporation into DNA and its effect on mutation rates
in human cancer cells. Nucleic Acids Res. 42:e1522014. View Article : Google Scholar : PubMed/NCBI
|
